ArticleRSC advances2020
Synthesis of controlled-size silver nanoparticles for the administration of methotrexate drug and its activity in colon and lung cancer cells.
Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 75 citations in OpenAlex.
- Potential of Silver Nanoparticles in Imaging Diagnostics and Image-Guided Applications: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Silver Nanoparticles (AgNPs) as a Double-Edged Sword: Synthesis, Factors Affecting, Mechanisms of Toxicity and Anticancer Potentials-An Updated Review till March 2025.Biological trace element research · 2026Review
- Nanoparticle technologies in precision oncology and personalized vaccine development: Challenges and advances.International journal of pharmaceutics: X · 2025Review
- Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Antitumor potential of silver nanoparticles against lung cancer: current trends, scope and relevance.3 Biotech · 2025Review
- Synergistic Antimicrobial Activity of BrSPR20-P1 Peptide and Silver Nanoparticles Against Pathogenic Bacteria.International journal of molecular sciences · 2025Article
- Recent Advances in the Application of Silver Nanoparticles for Enhancing Phototherapy Outcomes.Pharmaceuticals (Basel, Switzerland) · 2025Review
- NanoFlora: Unveiling the therapeutic potential of Ipomoea aquatica nanoparticles.Journal, genetic engineering & biotechnology · 2025Article
- Role of Nanomedicine for Targeted Drug Delivery in Livestock: Future Prospective.Pharmaceutical nanotechnology · 2025Review
- Influence of silver nanoparticles' size on their direct interactions with doxorubicin and its biological effects.Scientific reports · 2024Article
- Inorganic nanoparticle-based treatment approaches for colorectal cancer: recent advancements and challenges.Journal of nanobiotechnology · 2024Review
- Synthesis and Characterization of Paclitaxel-Loaded Silver Nanoparticles: Evaluation of Cytotoxic Effects and Antimicrobial Activity.Bioinorganic chemistry and applications · 2024Article
- Zebrafish in Lung Cancer Research.Cancers · 2023Review
- Phytofabrication of silver nanoparticles usingNanoscale advances · 2023Article
- Biogenic Silver Nanoparticles for Targeted Cancer Therapy and Enhancing Photodynamic Therapy.Cells · 2023Review
- Evolution of Gold and Iron Oxide Nanoparticles in Conjugates with Methotrexate: Synthesis and Anticancer Effects.Materials (Basel, Switzerland) · 2023Article
- Nano-biotechnology in tumour and cancerous disease: A perspective review.Journal of cellular and molecular medicine · 2023Review
- Graphitic Carbon Nitride Nanoheterostructures as Novel Platforms for the Electrochemical Sensing of the Chemotherapeutic and Immunomodulator Agent MTX.Biosensors · 2022Article
- Novel biodegradable molecularly imprinted polymer nanoparticles for drug delivery of methotrexate anti-cancer; synthesis, characterization and cellular studies.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A controlled synthesis of methotrexate (MTX) silver nanoparticles (AgNPs-MTX) using borohydride and citrate as reduction and reduction/capping agents, respectively, was performed in order to obtain AgNPs-MTX conjugates with a narrow size distribution. Their characterization showed polydispersed spherical shape nanoparticles with a mean size around 13 nm and distribution range between 7-21 nm. The presence of MTX was confirmed by FTIR and EDX analysis. Spectroscopic determinations suggest the chemisorption of MTX through a carboxylic group (-COOH) onto AgNPs
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.